NASDAQ:PBYI - Puma Biotechnology Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Puma Biotechnology Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $10.03 -0.58 (-5.47 %) (As of 02/28/2020 04:39 AM ET) Add Compare Today's Range$8.76Now: $10.03▼$10.4850-Day Range$7.71MA: $10.50▼$14.5752-Week Range$6.26Now: $10.03▼$43.90Volume2.16 million shsAverage Volume2.39 million shsMarket Capitalization$390.78 millionP/E RatioN/ADividend YieldN/ABeta1.77 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care. Its drug candidates include PB272 neratinib (oral) for the treatment of early stage breast cancer, metastatic breast cancer, non-small cell lung cancer, HER2 mutation-positive solid tumors, and HER2-mutated non-amplified breast cancer; and PB272 neratinib (intravenous). Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:PBYI Previous Symbol CUSIPN/A CIK1401667 Webhttp://www.pumabiotechnology.com/ Phone424-248-6500Debt Debt-to-Equity Ratio6.84 Current Ratio1.71 Quick Ratio1.67Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$272.30 million Price / Sales1.44 Cash FlowN/A Price / Cash FlowN/A Book Value$0.90 per share Price / Book11.14Profitability EPS (Most Recent Fiscal Year)($1.95) Net Income$-75,600,000.00 Net Margins-27.76% Return on Equity-275.17% Return on Assets-28.24%Miscellaneous Employees272 Outstanding Shares38,961,000Market Cap$390.78 million Next Earnings Date5/14/2020 (Estimated) OptionableOptionable Receive PBYI News and Ratings via Email Sign-up to receive the latest news and ratings for PBYI and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:PBYI Rates by TradingView Puma Biotechnology (NASDAQ:PBYI) Frequently Asked Questions What is Puma Biotechnology's stock symbol? Puma Biotechnology trades on the NASDAQ under the ticker symbol "PBYI." How were Puma Biotechnology's earnings last quarter? Puma Biotechnology Inc (NASDAQ:PBYI) announced its quarterly earnings data on Wednesday, November, 6th. The biopharmaceutical company reported ($0.44) EPS for the quarter, beating the consensus estimate of ($0.76) by $0.32. The biopharmaceutical company earned $56.40 million during the quarter, compared to the consensus estimate of $60.21 million. Puma Biotechnology had a negative net margin of 27.76% and a negative return on equity of 275.17%. The company's revenue was down 9.9% on a year-over-year basis. During the same period in the previous year, the business earned $0.16 earnings per share. View Puma Biotechnology's Earnings History. When is Puma Biotechnology's next earnings date? Puma Biotechnology is scheduled to release their next quarterly earnings announcement on Thursday, May 14th 2020. View Earnings Estimates for Puma Biotechnology. What price target have analysts set for PBYI? 10 analysts have issued 1-year target prices for Puma Biotechnology's stock. Their forecasts range from $6.00 to $17.00. On average, they expect Puma Biotechnology's share price to reach $12.38 in the next twelve months. This suggests a possible upside of 23.4% from the stock's current price. View Analyst Price Targets for Puma Biotechnology. What is the consensus analysts' recommendation for Puma Biotechnology? 10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Puma Biotechnology in the last year. There are currently 3 sell ratings, 6 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Puma Biotechnology. What are Wall Street analysts saying about Puma Biotechnology stock? Here are some recent quotes from research analysts about Puma Biotechnology stock: 1. According to Zacks Investment Research, "Puma Biotech's only marketed drug Nerlynx is approved for breast cancer in the United States and several other countries. A supplemental new drug application to include data from the NALA study on Nerlynx’s label is under review in the US. If approved, the company can gain access and treat an expanded patient population, which can drive sales higher in the future. Several other studies on Nerlynx targeting different types of breast cancer patients in earlier-line settings are also underway. However, Puma Biotech is totally dependent on Nerlynx for growth. Hence, any regulatory setback for Nerlynx will weigh heavily on the stock. Moreover, Nerlynx sales vary from quarter to quarter due to patient discontinuation, which is a persistent concern. Shares of the company have underperformed the industry in the past year." (1/8/2020) 2. Cowen Inc analysts commented, "Cidara reported 4Q18 financial results yesterday and we spoke w/ mgmt for an update. Phase 3 RESTORE trial of rezafungin in Candidemia/ Invasive Candidiasis was initiated last yr and enrollment rate is reportedly in line w/ expectations. Mgmt guiding for top-line results in mid-2020 (unch). Discussions are still ongoing w/ both EMA and FDA around Phase 3 RESPECT trial in prophylaxis. Mgmt nevertheless guiding for initiation in 1H19. Top-line results from Phase 2 STRIVE B trial likely mid-2019. We assume safety/ efficacy profile similar to STRIVE A. Company reported impressive progress w/ a Cloudbreak Influenza candidate last yr and expects to nominate a development candidate 1Q19. BUY. We acknowledge cash constraints, but believe stock does not adequately reflect value of pipeline." (3/1/2019) 3. Cantor Fitzgerald analysts commented, ": Reiterate OW rating; increasing PT to $57/share. Nerlynx roared in 4Q, and 2019 guidance beats expectations. US Nerlynx sales were $61M vs. $53M consensus. Although gross to net was lower in 4Q, we think that 4Q represents a solid beat, and we saw growth in bottles of 12%. In addition, the company’s 2019 US guidance of $255-280M announced on the call exceeded expectations of $238M. Lastly, the company had its first cash flow positive quarter at ~$8M. Shares have recovered by 59% from their early November lows, but we think that there remains upside to shares from Nerlynx growth. We spoke to management post call and we highlight some of our key takes below." (2/28/2019) Has Puma Biotechnology been receiving favorable news coverage? Media coverage about PBYI stock has been trending negative recently, according to InfoTrie Sentiment. The research firm identifies negative and positive press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Puma Biotechnology earned a news impact score of -2.7 on InfoTrie's scale. They also assigned media stories about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View News Stories for Puma Biotechnology. Are investors shorting Puma Biotechnology? Puma Biotechnology saw a increase in short interest during the month of January. As of January 31st, there was short interest totalling 7,820,000 shares, an increase of 12.4% from the January 15th total of 6,960,000 shares. Based on an average daily volume of 1,760,000 shares, the days-to-cover ratio is currently 4.4 days. Currently, 23.2% of the shares of the company are short sold. View Puma Biotechnology's Current Options Chain. Who are some of Puma Biotechnology's key competitors? Some companies that are related to Puma Biotechnology include Corcept Therapeutics (CORT), Constellation Pharmaceuticals (CNST), Endo International (ENDP), Amneal Pharmaceuticals (AMRX), Dicerna Pharmaceuticals (DRNA), Innoviva (INVA), ZEALAND PHARMA/S (ZEAL), Theravance Biopharma (TBPH), Madrigal Pharmaceuticals (MDGL), Nabriva Therapeutics (NBRV), TG Therapeutics (TGTX), Intra-Cellular Therapies (ITCI), Zogenix (ZGNX), Y-mAbs Therapeutics (YMAB) and Akebia Therapeutics (AKBA). What other stocks do shareholders of Puma Biotechnology own? Based on aggregate information from My MarketBeat watchlists, some companies that other Puma Biotechnology investors own include Medivation (MDVN), BioMarin Pharmaceutical (BMRN), Incyte (INCY), First Solar (FSLR), Dynavax Technologies (DVAX), United Continental (UAL), Kite Pharma (KITE), Array Biopharma (ARRY), Freeport-McMoRan (FCX) and Celgene (CELG). Who are Puma Biotechnology's key executives? Puma Biotechnology's management team includes the folowing people: Mr. Alan H. Auerbach, Founder, Chairman, Pres, CEO & Sec. (Age 49)Dr. Richard P. Bryce, Chief Medical & Scientific Officer (Age 62)Mr. Steven Lo, Chief Commercial Officer (Age 52)Mr. Charles R. Eyler, Sr. VP of Fin. & Admin. and Treasurer (Age 71)Mr. Maximo F. Nougues, CFO & Principal Accounting Officer (Age 50) Who are Puma Biotechnology's major shareholders? Puma Biotechnology's stock is owned by many different of retail and institutional investors. Top institutional investors include State Street Corp (9.00%), Fred Alger Management LLC (4.55%), Palo Alto Investors LP (3.46%), Acadian Asset Management LLC (2.15%), Goldman Sachs Group Inc. (1.97%) and Geode Capital Management LLC (1.45%). Company insiders that own Puma Biotechnology stock include Alan H Auerbach, Charles R Eyler, Douglas M Hunt and Richard Paul Bryce. View Institutional Ownership Trends for Puma Biotechnology. Which institutional investors are selling Puma Biotechnology stock? PBYI stock was sold by a variety of institutional investors in the last quarter, including UBS Group AG, Goldman Sachs Group Inc., Candriam Luxembourg S.C.A., Point72 Asset Management L.P., FMR LLC, Rafferty Asset Management LLC, Palo Alto Investors LP and Rice Hall James & Associates LLC. Company insiders that have sold Puma Biotechnology company stock in the last year include Alan H Auerbach, Douglas M Hunt and Richard Paul Bryce. View Insider Buying and Selling for Puma Biotechnology. Which institutional investors are buying Puma Biotechnology stock? PBYI stock was bought by a variety of institutional investors in the last quarter, including State Street Corp, Acadian Asset Management LLC, Geode Capital Management LLC, Credit Suisse AG, Fred Alger Management LLC, Oxford Asset Management LLP, Renaissance Technologies LLC and Schonfeld Strategic Advisors LLC. View Insider Buying and Selling for Puma Biotechnology. How do I buy shares of Puma Biotechnology? Shares of PBYI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is Puma Biotechnology's stock price today? One share of PBYI stock can currently be purchased for approximately $10.03. How big of a company is Puma Biotechnology? Puma Biotechnology has a market capitalization of $390.78 million and generates $272.30 million in revenue each year. The biopharmaceutical company earns $-75,600,000.00 in net income (profit) each year or ($1.95) on an earnings per share basis. Puma Biotechnology employs 272 workers across the globe.View Additional Information About Puma Biotechnology. What is Puma Biotechnology's official website? The official website for Puma Biotechnology is http://www.pumabiotechnology.com/. How can I contact Puma Biotechnology? Puma Biotechnology's mailing address is 10880 WILSHIRE BOULEVARD SUITE 2150, LOS ANGELES CA, 90024. The biopharmaceutical company can be reached via phone at 424-248-6500 or via email at [email protected] MarketBeat Community Rating for Puma Biotechnology (NASDAQ PBYI)Community Ranking: 2.5 out of 5 ( )Outperform Votes: 501 (Thanks for Voting!)Underperform Votes: 482 (Thanks for Voting!)Total Votes: 983MarketBeat's community ratings are surveys of what our community members think about Puma Biotechnology and other stocks. Vote "Outperform" if you believe PBYI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PBYI will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 2/28/2020 by MarketBeat.com StaffFeatured Article: What is Cost of Goods Sold (COGS)?
